Skip to main content

Advertisement

SpringerLink
Log in

Severe thrombocytopenia in connective tissue diseases: a single-center review of 131 cases

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

To analyze the clinical characteristics of severe thrombocytopenia in patients with various connective tissue diseases (CTDs), one hundred thirty-one consecutive CTD patients with blood platelet count less than 20 × 109/L on admission, which was ascribed to the nature of diseases, during January 2011 to June 2015 in our department were enrolled and checked for their survival status in September 2015. The patients were categorized based on background diseases or therapeutic effects, and compared with clinical features, treatment strategies, and long-term outcomes among the groups. Cumulative survival rates were estimated using Kaplan-Meier analysis. Of the patients, 88.5% were female. The most frequently seen background diseases were primary Sjögren’s syndrome (pSS) (53.4%) and systemic lupus erythematosus (SLE) (40.5%). Age on admission for SLE patients (36.7 ± 14.1 years) was much younger than that for other patients (44.4 ± 15.4 years for pSS and 46 ± 16.1 years for other CTDs, p < 0.05). Ninety-six cases accompanied with various bleeding symptoms, which were more common in pSS patients than in SLE patients (80.0% vs. 64.2%, p < 0.05). Glucocorticoids and/or intravenous immunoglobulin were applied as initial therapy with an overall response rate of 36.6%. For patients failed to respond, immunosuppressive drugs were added and the other 22.8% benefited from the treatment. Compared to those ineffective to the aforementioned drugs, patients with therapeutic effects had significantly high immunoglobulin G levels. Twenty patients with refractory diseases accepted mesenchymal stem cell transplantation (MSCT) with a total effective rate of 65.0%. Eleven patients died after the follow-up for a mean time of 27.7 months, of which 7 were associated with hemorrhage. There was no difference in the survival rate among different background diseases. However, compared with those who did not gain remission, patients achieved partial or complete remission had better cumulative survival rates (p < 0.01). In conclusion, among various CTDs, severe thrombocytopenia often occurs in patients with SLE or pSS. Early response to the treatments, but not the background disease, is an important predictor of long-term prognosis. For patients with refractory thrombocytopenia, MSCT may provide an alternative therapeutic strategy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Fayyaz A, Igoe A, Kurien B et al (2015) Haematological manifestations of lupus. Lupus Sci Med 2:e000078

    Article  Google Scholar 

  2. Sultan SM, Begum S, Isenberg DA (2003) Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems. Rheumatology 42:230–234

    Article  CAS  Google Scholar 

  3. Mok CC, Lee KW, Ho CT, Lau CS, Wong RW (2000) A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology 39:399–406

    Article  CAS  Google Scholar 

  4. Ziakas PD, Giannouli S, Zintzaras E, Tzioufas AG, Voulgarelis M (2005) Lupus thrombocytopenia: clinical implications and prognostic significance. Ann Rheum Dis 64:1366–1369

    Article  CAS  Google Scholar 

  5. Jiang B, Li T, Guo L, Shen H, Ye S, Chen S (2015) Efficacy and safety of rituximab in systemic lupus erythematosus and Sjogren syndrome patients with refractory thrombocytopenia: a retrospective study of 21 cases. J Clin Rheumatol 21:244–250

    Article  Google Scholar 

  6. Sardesai VV, Sardesai VR, Agarwal TD (2015) Steroid-resistant autoimmune thrombocytopenia in systemic lupus erythematosus treated with rituximab. Indian J Dermatol 60:106

    Article  Google Scholar 

  7. Arnal C, Piette JC, Leone J et al (2002) Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol 29:75–83

    CAS  PubMed  Google Scholar 

  8. Jung JH, Soh MS, Ahn YH, Um YJ, Jung JY, Suh CH, Kim HA (2016) Thrombocytopenia in systemic lupus erythematosus: clinical manifestations, treatment, and prognosis in 230 patients. Medicine 95:e2818

    Article  CAS  Google Scholar 

  9. Tan EM, Cohen AS, Fries JF, Masi AT, Mcshane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277

    Article  CAS  Google Scholar 

  10. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725

    Article  CAS  Google Scholar 

  11. Silman AJ (1988) The 1987 revised American Rheumatism Association criteria for rheumatoid arthritis. Br J Rheumatol 27:341–343

    Article  CAS  Google Scholar 

  12. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH, European Study Group on Classification Criteria for Sjögren's Syndrome (2002) Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554–558

    Article  CAS  Google Scholar 

  13. Criteria for diagnosis of Behcet's disease (1990) International study group for Behcet’s disease. Lancet 335:1078–1080

    Google Scholar 

  14. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347

    Article  CAS  Google Scholar 

  15. Mosca M, Neri R, Bombardieri S (1999) Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol 17:615–620

    CAS  PubMed  Google Scholar 

  16. Schuppan D, Afdhal NH (2008) Liver cirrhosis. Lancet 371:838–851

    Article  CAS  Google Scholar 

  17. Miyakis S, Lockshin MD, Atsumi et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306

    Article  CAS  Google Scholar 

  18. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, Austin A, Bell A, Bloch DA, Corey PN, Decker JL, Esdaile J, Fries JF, Ginzler EM, Goldsmith CH, Hochberg MC, Jones JV, Riche NGHL, Liang MH, Lockshin MD, Muenz LR, Sackett DL, Schur PH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630–640

    Article  CAS  Google Scholar 

  19. Seror R, Ravaud P, Mariette X et al (2011) EULAR Sjogren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren’s syndrome. Ann Rheum Dis 69:1103–1109

    Article  Google Scholar 

  20. Koreth R, Weinert C, Weisdorf DJ, Key NS (2004) Measurement of bleeding severity: a critical review. Transfusion 44:605–617

    Article  Google Scholar 

  21. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kuhne T, Ruggeri M, George JN (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113:2386–2393

    Article  CAS  Google Scholar 

  22. Klepfish A, Friedman J, Schechter Y, Schattner A (2001) Autoimmune neutropenia, thrombocytopenia and Coombs positivity in a patient with primary Sjogren’s syndrome. Rheumatology 40:948–949

    Article  CAS  Google Scholar 

  23. Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, del Pino-Montes J, Calvo-Alen J, Jiménez-Alonso J, Micó ML, Beltrán J, Belenguer R, Pallarés L, GEMESS Study Group (2008) Primary Sjogren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine 87:210–219

    Article  CAS  Google Scholar 

  24. Fernandez M, Calvo-Alen J, Bertoli AM et al (2007) Systemic lupus erythematosus in a multiethnic US cohort (LUMINA L II): relationship between vascular events and the use of hormone replacement therapy in postmenopausal women. J Clin Rheumatol 13:261–265

    Article  Google Scholar 

  25. Jallouli M, Frigui M, Marzouk S, Snoussi M, Kechaou M, Kaddour N, Masmoudi H, Elloumi M, Bahloul Z (2012) Clinical implications and prognostic significance of thrombocytopenia in Tunisian patients with systemic lupus erythematosus. Lupus 21:682–687

    Article  CAS  Google Scholar 

  26. Chugh S, Darvish-Kazem S, Lim W, Crowther MA, Ghanima W, Wang G, Heddle NM, Kelton JG, Arnold DM (2015) Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol 2:e75–e81

    Article  Google Scholar 

  27. Xu J, Wang D, Liu D, Fan Z, Zhang H, Liu O, Ding G, Gao R, Zhang C, Ding Y, Bromberg JS, Chen W, Sun L, Wang S (2012) Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjogren syndrome. Blood 120:3142–3151

    Article  CAS  Google Scholar 

  28. Wang D, Huang S, Yuan X, Liang J, Xu R, Yao G, Feng X, Sun L (2017) The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus. Cell Mol Immunol 14:423–431

    Article  CAS  Google Scholar 

  29. Feng X, Che N, Liu Y, Chen H, Wang D, Li X, Chen W, Ma X, Hua B, Gao X, Tsao BP, Sun L (2014) Restored immunosuppressive effect of mesenchymal stem cells on B cells after olfactory 1/early B cell factor-associated zinc-finger protein down-regulation in patients with systemic lupus erythematosus. Arthritis Rheumatol 66:3413–3423

    Article  CAS  Google Scholar 

  30. Wang D, Zhang H, Liang J, Li X, Feng X, Wang H, Hua B, Liu B, Lu L, Gilkeson GS, Silver RM, Chen W, Shi S, Sun L (2013) Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. Cell Transplant 22:2267–2277

    Article  Google Scholar 

  31. Sun L, Wang D, Liang J, Zhang H, Feng X, Wang H, Hua B, Liu B, Ye S, Hu X, Xu W, Zeng X, Hou Y, Gilkeson GS, Silver RM, Lu L, Shi S (2010) Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum 62:2467–2475

    Article  CAS  Google Scholar 

Download references

Funding

This work is financially supported by the National Natural Science Foundation of China (81771745), Jiangsu Provincial Medical Talent Program (ZDRCA2016059), and Jiangsu Provincial Special Program of Medical Science (BE2015602).

Author information

Authors and Affiliations

  1. Department of Rheumatology and Immunology, Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, 210008, People’s Republic of China

    Wei Zhang, Fan Wang, Hong Wang, Bingzhu Hua, Xuebing Feng & Lingyun Sun

Authors
  1. Wei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bingzhu Hua
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xuebing Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lingyun Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Xuebing Feng or Lingyun Sun.

Ethics declarations

Disclosures

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, W., Wang, F., Wang, H. et al. Severe thrombocytopenia in connective tissue diseases: a single-center review of 131 cases. Clin Rheumatol 37, 3337–3344 (2018). https://doi.org/10.1007/s10067-018-4312-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-018-4312-y

Keywords

Search

Navigation